Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Valeo Pharma Inc VPHIF

Healthcare
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.


GREY:VPHIF - Post by User

Valeo Pharma Inc > Question for longs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(51)
•••
Comment by kooter33on Feb 16, 2021 1:02am
171 Views
Post# 32570861

RE:Question for longs

RE:Question for longs
Troy23 wrote: I like the potential here but considering the latest financial report ended July 31st where they reported 1.49 million in revs...cost of goods was 1,36 million, how can you have a decent bottom line when your gross margin is so small?? Even if they grow revenue to 50 million, if their cost of goods is 49 millions, there is no business here...?? 

Huh?  its called COVID delays for HC drug approvals.  Oct 31st 2020 YE report coming out last week of February 2021. Check it out.  CFO has stated they will be EBDITA +ve for the YE.  2021 will be the breakout year for VPH. Don't buy, just wait qand watch.  GL.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities